LLY.US Overview

Stock Performance: PHARMARON's stock surged 12.6% to $20.94 in early Hong Kong trading, reaching a peak of $21.06 during the session.

Short Selling Data: The company experienced short selling of $826.45K, with a short selling ratio of 1.703%.

Partnership Announcement: PHARMARON announced a production cooperation agreement with Eli Lilly for the oral small-molecule GLP-1 receptor agonist, Orforglipron.

Investment Details: Eli Lilly is set to invest $200 million in PHARMARON to enhance its technological capabilities, with plans for future expansion of the partnership.

Novo Nordisk Stock Decline: Novo Nordisk's stock fell by 10.9% to DKK268.2 following disappointing trial results for its weight loss drug CagriSema, which showed less effectiveness compared to Eli Lilly's drug.

CagriSema Trial Results: In an 84-week trial, CagriSema resulted in a 20.2% weight reduction, while Eli Lilly's tirzepatide achieved a 23.6% reduction, contributing to a 4.5% increase in Eli Lilly's stock price.

Strategic Partnership: INNOVENT BIO has formed a strategic partnership with Eli Lilly to co-develop new biological drugs targeting oncology and immunology globally, as reported by JPMorgan.

Positive Market Reaction: JPMorgan views this collaboration as a significant milestone for INNOVENT BIO, enhancing its reputation as a global biopharmaceutical company and showcasing its strong R&D capabilities.

Stock Performance: Following the announcement, INNOVENT BIO's stock rose by 5.386%, with a short selling ratio of 19.306% and a total short selling amount of $259.46 million.

Analyst Ratings: CICC has raised its earnings forecast for INNOVENT BIO and reaffirmed it as a top pick among Chinese biotech firms, while JPMorgan assigned an Overweight rating with a target price of HKD111.

Collaboration Announcement: INNOVENT BIO and Eli Lilly have formed a partnership focused on early-stage oncology and immunology assets, involving an upfront payment of USD350 million and potential milestone payments up to USD8.5 billion.

New Partnership Model: UBS views this collaboration as a novel partnership model, differing from previous out-licensing deals, as it includes the creation of a new company for joint development of assets not previously in INNOVENT BIO's pipeline.

Licensing Agreement: INNOVENT BIO has licensed overseas rights for certain oncology and immunology assets to Eli Lilly, receiving an upfront payment of USD 350 million and potential milestone payments of around USD 8.5 billion.

Positive Market Reaction: CLSA views the transaction positively, indicating it reflects the recognition of INNOVENT BIO's R&D capabilities by a major global pharmaceutical company.

Target Price Adjustment: Following the announcement, CLSA has raised its target price for INNOVENT BIO from HKD 120.1 to HKD 130.2 while maintaining an Overweight rating.

Short Selling Data: As of February 9, 2026, INNOVENT BIO has a short selling amount of $259.46 million, with a short selling ratio of 19.306%.

Strategic Collaboration: INNOVENT BIO has partnered with Eli Lilly to enhance the global development of innovative oncology and immunology drugs, involving an upfront payment of USD 350 million and potential milestone payments of up to USD 8.5 billion.

Market Analysis: Goldman Sachs reports that INNOVENT BIO's stock is currently undervalued, with a target price of HKD 102.85, based on a risk-adjusted discounted cash flow analysis, despite a high market-implied cost of capital.